Back to search
Hematoma, Subdural
Clinical trial pipeline · Data from ClinicalTrials.gov
See which Hematoma, Subdural trials you may qualify forClinical trial pipeline · Data from ClinicalTrials.gov
See which Hematoma, Subdural trials you may qualify forObjective: To follow people with GISTs and collect tumor tissue so that it can be studied in the lab. Eligibility: People age 6 and older who have a GIST. D…
This study aims to investigate the effectiveness and safety of body posture to improve intracranial pressure in preventing postoperative recurrence for chronic…
Chronic subdural hematoma (cSDH) is a very common disease, primarily affecting older people, and is associated with significant morbidity and mortality. The inc…
The purpose of this study is to determine how effective the drug pemigatinib is as a treatment option for advanced succinate dehydrogenase (SDH)-deficient gastr…
The aim of the study is to proof the effectiveness of Histoacryl® on preventing recurrence or progression of subdural hematoma after embolization of the middle…
The goal of this clinical trial is to investigate the efficacy and safety of temozolomide in SDH deficiency GIST patients.
This is a prospective, randomized, controlled, open-label, blinded endpoint (PROBE) clinical investigation in which patients with non-emergent chronic subdural…
EMMA-Can is a prospective randomized open-label, blinded end point (PROBE) study, that will assess the recurrence risk and safety of embolization of the middle…